repeat testing at progression of egfr nsclc
Published 4 years ago • 43 plays • Length 7:41Download video MP4
Download video MP3
Similar videos
-
3:31
osimertinib changed the treatment paradigm for repeat molecular testing at progression?
-
2:50
optimizing therapy at progression of egfr-mutant nsclc
-
3:41
what is the rationale for repeat molecular testing at progression?
-
2:21
treatment of egfr nsclc after progression
-
59:37
refining biomarker testing and targeted treatment of nsclc with egfr mutations
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
2:44
mutation testing at progression of alk-rearranged nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
3:36
testing and recommendations: egfr-mutated stage iv nsclc
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
20:34
2021 west oncology | lung cancer | egfr mutation therapy resistance and adcs and trop2
-
9:30
egfr testing for nsclc
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
2:08
value of repeat mutation testing for alk nsclc
-
1:02:05
adjuvant egfr-targeted therapy as a game changer in multimodal nsclc management
-
43:35
maximizing the impact of egfr-targeted therapy in resectable nsclc
-
1:22:21
egfr breakout video targeted therapies 2017
-
3:12
egfr-tki therapy in advanced nsclc